


See "Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study" on page 223.



Supplementary Fig. 1. Comparison of trough levels of infliximab (IFX) between assay A and assay B. Trough levels of IFX (TLI) were measured in the loss of response (LOR) (A) and remission (B) groups using assays A and B. Serum drawn immediately before IFX infusion was used for TLI measurements. Mean TLI values with assays A and B are $2.4 \pm 3.2 \mu\text{g/mL}$ vs. $2.3 \pm 2.7 \mu\text{g/mL}$ ($P=0.33$) in the LOR group (A), and $5.2 \pm 4.2 \mu\text{g/mL}$ vs. $5.2 \pm 3.8 \mu\text{g/mL}$ ($P=0.85$) in the remission group (B), respectively.